Stevan Gonzalez, MD
Transplant Hepatology · Fort Worth, TXNPI 1013184985
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $207,000 of the $282,355 with a category attached, or 73.3%. Mallinckrodt Hospital Products Inc. accounts for 71.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $72,300 and has fallen 70.4% since, to $21,428 in 2025. Among transplant hepatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $866.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$202K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$52K
- AbbVie$27K
- Gilead$869
- Intercept Pharmaceuticals, Inc.$520
- Merck$87
- plus $227 from 6 others
Across 75 payments — averaging $3108.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$143K
- Mallinckrodt Enterprises LLC$90K
What the payments were for
- Consulting fees$47,23317%
- Speaking & faculty fees$207,00073%
- Travel & lodging$20,7317%
- Food & beverage$7,3843%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 137 | $202,160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $51,875 |
| AbbVie | 88 | $26,618 |
| Gilead | 35 | $869 |
| Intercept Pharmaceuticals, Inc. | 1 | $520 |
| Merck | 1 | $87 |
| Mallinckrodt Enterprises LLC | 1 | $73 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Eisai Inc. | 2 | $43 |
| Veloxis Pharmaceuticals, Inc. | 1 | $22 |
| Shionogi Inc | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$282,355 in reported general payments places this provider in the 95th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 178 | $607,005 |
| Sirolimus | 97 | $34,215 |
| KristaloseLactulose | 17 | $30,118 |
| Ursodiol | 147 | $23,750 |
| Mycophenolic AcidMycophenolate Sodium | 47 | $12,649 |
| Tacrolimus | 109 | $11,795 |
| Cyclosporine ModifiedCyclosporine, Modified | 29 | $4,981 |
| Entecavir | 72 | $4,543 |
| Azathioprine | 94 | $2,910 |
| ConstuloseLactulose | 26 | $2,192 |
| Mycophenolate Mofetil | 20 | $1,928 |
| Spironolactone | 83 | $1,448 |
| Lactulose | 25 | $1,163 |
| Amiloride Hcl | 30 | $978 |
| Pantoprazole Sodium | 40 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $51,875 | $607,005178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 transplant hepatology providers in Texas.
Other transplant hepatology in Fort Worth
- Shivang MehtaFort Worth$6K
- Themistoklis KourkoumpetisFort Worth$3K
- Omar HaqFort Worth$2K
- Abdullah MubarakTyler$362K
- Fernando MembrenoMcAllen$258K
- David VictorHouston$249K
- Prasun JalalHouston$247K
- Carmen LandaverdeSan Antonio$189K
- Hector NazarioDallas$161K
- Ashwini MehtaDallas$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.